Company: OTSA
Filing Date: 2025-06-09
Form Type: F-1
Source: 0001213900-25-052720
Chunk: 33

Company: OTSAW Ltd
Filing Date: 2025-06-09
Form: F-1
Chunk 33
---
, distribute and service our products, our margins, profitability and prospects would be materially and adversely affected. Therefore, we may be unable to adequately control the substantial costs associated with our operations, and our costs may grow more quickly than our revenues, harming our business and profitability. An inability to generate positive cash flow for the near term may adversely affect our ability to raise needed capital for our business on reasonable terms, diminish supplier or customer willingness to enter into transactions with us and have other adverse effects that may decrease our long -termviability. We may not achieve positive cash flow in the near future or at all. We made, and expect to continue to make, significant investments in research and development that may not achieve expected returns. Our research and development capabilities are the pillars of our core outdoor autonomy and software competence. We will continue to make significant investments in research and development, expansion of product offerings and improvement for existing products, services and technologies. We are in the research and development stage of upgrading our proprietary software technology, the ANS, from Version 2 to Version 3. We intend for Version 3 to be a commercial software solution that will provide a foundational outdoor autonomy capability for third -partyAMR products, AMR frameworks or hardware platforms, under the product brand “Odyssey”. Furthermore, as part of our joint venture with Swisslog Healthcare Holding AG (“Swisslog Healthcare”), we are developing the next -generationof TransCar solutions for hospitals intralogistics. We are in the research and development stage of upgrading Swisslog Healthcare’s TransCar system to the next generation of TransCar, Transcar 5.0, by utilizing our core software technologies and robotics autonomy and mobility expertise. 16 Because we account for research and development costs as operating expenses, these expenditures will adversely affect our earnings in the future. Our research and development efforts and investments may not be successful, and our new products and services may not achieve market acceptance, create any additional revenue or become profitable if customers do not perceive our product and service offerings as providing significant new functionality or value. We may not achieve material revenue from our new products, services, and technologies. Our competitors may surpass us in technological innovation, hindering our ability to commercialize new and competitive products that meet the needs and demands of the market in a timely manner or at all, which consequently may adversely impact our operating results as well as our reputation. Our limited operating history makes it difficult to evaluate our business, prospects, and future viability, and may increase the risk of your investment. Any evaluation of